Loading
A phase 1 trial of MNPR-101 run by Monopar Therapeutics, active and no longer recruiting.
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors is a phase 1 interventional study registered as NCT06617169 by Monopar Therapeutics, with 12 participants planned, started 2024-10-08. Conditions recorded: Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer and Pancreatic Cancer. Interventions recorded: MNPR-101-PCTA-177Lu.
Shares Monopar Therapeutics, MNPR-101, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/